Categories Earnings, Retail

Ascena Retail Group (NASDAQ: ASNA): Q2 2020 Earnings Snapshot

— Ascena Retail Group Inc. (NASDAQ: ASNA) reported a second-quarter 2020 net loss of $97.4 million or $9.76 per share, wider than a loss of $71.5 million or $7.24 per share in the previous year quarter.

— Adjusted loss from continuing operations was $4.95 per share, which reflects the 1-for-20 reverse stock split that became effective during the second quarter.

Earnings Update by AlphaStreet

— Revenue declined by 4% to $1.22 billion versus $1.45 billion expected. This primarily reflects a comparable sales decrease of 2% for the quarter, a decline in other revenue and a decrease in non-comparable sales.

— During the quarter, Ascena incurred non-cash impairment charges of goodwill and other intangible assets. This offset in part by the benefit of cost reductions.

— At the end of the second quarter, the company had cash and cash equivalents of $374 million while the total debt stood at $1.29 billion, which represents the balance remaining on the term loan.

— Looking ahead into the third quarter, the company expects net sales in the range of $1.05-1.08 billion and comparable sales in the negative low-single digits range. The consensus estimates revenue of $1.3 billion.

— Gross margin is predicted to be in the range of 57.8-58.3% and adjusted operating loss is projected to be in the range of $30-10 million for the third quarter.

— For the full year, the company continues to expect the total capital spending to be in the range of $80-100 million, which represents a significant decrease compared to prior years.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Also Read:  Infographic: How Navistar (NAV) performed in Q3 2020

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results

Top